31 results about "Severe acute respiratory syndrome coronavirus RNA" patented technology

The present invention provides a cDNA of a severe acute respiratory syndrome (SARS) coronavirus, recombinant SARS coronavirus vectors, and SARS coronavirus replicon particles. Also provided are methods of making the compositions of this invention and methods of using the compositions as immunogens and/or vaccines and/or to express heterologous nucleic acids.

The disclosure provides methods and compositions useful for inhibiting virus requiring membrane fusion for viral entry, specifically for inhibiting severe acute respiratory syndrome coronavirus (SARS-CoV), Ebola virus (EBOV), Hendra (HeV) and Nipah (NIV) viruses by targeting Cathepsin-L (CatL) cleavages sites in the viruses' glycoproteins.

Methods for the rapid detection of the presence or absence of SARS-CoV-2 in biological or non-biological samples are described. These methods are adapted to be performed rapidly in a point-of-care setting. The methods can include performing an amplifying step, a hybridizing step, and a detecting step. Specifically, primers and probes targeting SARS-CoV-2 are provided that are designed for the detection of this target. Additionally, kits and reaction vessels containing primers and probes targeting SARS-CoV-2 are provided. Additionally, methods, kits and reaction vessels for the simultaneous rapid detection of the presence or absence of SARS-CoV-2, influenza A, and influenza B in biological or non-biological samples are described.

The invention relates to application of a Shuanghuanglian preparation in virus infection resistance. Specifically, the invention provides an application of a chlorogenic acid compound or a pharmaceutically acceptable salt or an extract of the chlorogenic acid compound. Experiments show that the Shuanghuanglian preparation (oral liquid) and the active ingredient chlorogenic acid thereof have obvious antiviral effects on severe acute respiratory syndrome coronavirus (SARS-CoV), influenza virus (influenza virus), Middle East Respiratory Syndrome (MERS) and 2019-nCoV (new coronavirus), and prove that the Chinese patent medicine Shuanghuanglian preparation (oral liquid) can be used for treating virus infectious diseases.

The present invention provides methods for treatment and prevention of Coronavirus Disease 2019 (COVID-19) and any clinical presentations associated with it including Acute Respiratory Distress Syndrome (ARDS), Severe Inflammatory Response Syndrome (SIRS), and/or any state corresponding to a severe acute attack of an inflammatory pathology causing an exacerbation of cytokine storm associated with unregulated oxidative, endoplasmic reticulum, and inflammatory stress mediated cytotoxic effects following the infection with the novel Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) with at least a pharmacologically acceptable trace element, Selenium (Se) containing molecule, or compound, or drug, or injection, or intravenous infusion. This is achieved by administering to a subject, a therapeutically effective amount of at least a pharmacologically acceptable molecule containing Se at an initial high dose followed by reduced, continuous dosing in subsequent treatment so as to employ its antioxidant, cytokine-modulating, antiviral, immune-enhancing, anti-apoptotic, and anticoagulant properties for the treatment and prevention of COVID-19.

A method for detecting the presence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in a biological sample includes the steps of lysing the biological sample to form a lysate and generating an amplified lysate by performing a nucleic acid sequence-based (NASBA) amplification for a target nucleic acid sequence in the lysate in the presence of: a forward primer having the oligonucleotide sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 5, SEQ ID NO: 9, SEQ ID NO: 13, and SEQ ID NO: 17; a reverse primer having the oligonucleotide sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 6, SEQ ID NO: 10, SEQ ID NO: 14, and SEQ ID NO: 18; and a molecular beacon having the oligonucleotide sequence selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 7, SEQ ID NO: 11, SEQ ID NO: 15, and SEQ ID NO: 19 and a fluorophore. The amplified lysate is exposed to an excitation source. A fluorescence of the fluorophore is detected in the amplified lysate exposed to the excitation source The SARS-CoV-2 is determined to be present in the biological sample in response to detecting the fluorescence of the fluorophore.

The invention discloses application of a small molecule compound sodium phytate hydrate in preparation of a medicine for resisting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); the medicine for resisting the SARS-CoV-2 is a pharmaceutical composition which takes the sodium phytate hydrate as a unique active ingredient or contains the sodium phytate hydrate; and the medicine for resisting the SARS-CoV-2 is a medicine for preventing or treating SARS-CoV-2 infection. According to the invention, an SARS-CoV-2 susceptible cell line, including African green monkey kidney cells Vero E6 and human lung adenocarcinoma cells Calu-3, is utilized to detect the anti-SARS-CoV-2 activity of the sodium phytate hydrate. Experimental results show that the sodium phytate hydrate can effectively inhibit infection of the SARS-CoV-2 on the susceptible cells, is relatively low in cytotoxicity, is expected to be used as a medicine for effectively resisting SARS-CoV-2 infection, and has an application prospect.

The invention relates to the technical field of medicines, and relates to application of an ansatriene compound in preparation of medicines or pharmaceutical compositions for resisting infection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), tick-borne encephalitis virus (TBEV), west nile virus (WNV), yellow fever virus (YFV) and chikungunya fever virus (CHIKV) and a preparation method of the ansatriene compound.

The invention relates to application of nelfinavir in preparation of a medicine for preventing and treating COVID-19. Specifically, the invention relates to application of nelfinavir and a pharmaceutical composition thereof as a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 or 2019-nCoV) inhibitor in preparation of drugs for treating and/or preventing and relieving respiratory tract infection, pneumonia and other related diseases caused by 2019-nCoV infection.

The invention provides a lateral flow device and methods for the detection of antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a sample of bodily fluid of an animal or human. The test methods include contacting the sample with a conjugate comprising a recombinant SARS-CoV-2 spike protein antigen that has been conjugated to a detection agent, wherein an antigen-antibody complex is formed between the SARS-CoV-2 spike protein antigen conjugate and SARS-CoV-2 antibodies present in the sample; capturing the formed antigen-antibody complex with an Fc-binding molecule; and detecting the captured complex.

A system for detecting the presence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in a biological sample includes a sampling device, a lysing chamber, a NASBA fluidic network, and an analytical instrument. The sampling device is configured to contain a sample containing a pathogen target sequence for SARS-CoV-2. The lysing chamber is configured to be in fluid communication with the sampling device to receive the sample. The is lysing chamber is configured to lyse the sample into a lysate. The NASBA fluidic network is configured to be in fluid communication with the lysing chamber to receive the lysate. The NASBA fluidic network includes an enzyme, a forward primer, and a reverse primer for amplifying a predetermined genetic sequence in the pathogen target sequence contained within the lysate. The forward primer has the oligonucleotide sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 5, SEQ ID NO: 9, SEQ ID NO: 13, and SEQ ID NO: 17. The reverse primer has the oligonucleotide sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 6, SEQ ID NO: 10, SEQ ID NO: 14, and SEQ ID NO: 18. A molecular beacon is configured to attach to the pathogen target sequence. The beacon has the oligonucleotide sequence selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 7, SEQ ID NO: 11, SEQ ID NO: 15, and SEQ ID NO: 19 and a fluorophore. The analytical instrument is configured to excite the beacon when the molecular beacon is attached to the pathogen target sequence to signal a presence of the pathogen target sequence.

The present disclosure relates to a method for preparing an antibody, an antibody, a nucleic acid encoding the antibody, and an engineered cell. The antibody provided by the invention can resist severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and is good in specificity, high in sensitivity and excellent in pathogen neutralization effect.

Disclosed herein is a recombinant antibody against the nucleocapsid protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). A kit containing the recombinant antibody for use in coronavirus detection is encompassed in the present disclosure. Also disclosed herein are in vitro methods of detecting coronavirus infection in a subject with the aid of the recombinant antibody.

Disclosed herein are methods for treating an individual having a Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection. The method may comprise administering a JAK inhibitor, for example ruxolitinib (JAKAFI®), to an individual in need thereof, such individual generally being an individual having, or suspecting of having, SARS-CoV-2 infection. The individual in need thereof may be an individual having, or suspected of having or at risk for developing SARS-CoV-2 infection-related cytokine storm. The individual in need thereof may further be an individual having, or suspected of having SARS-CoV-2 infection-related pneumonia.